Ignite Creation Date:
2025-12-25 @ 2:30 AM
Ignite Modification Date:
2025-12-27 @ 11:12 PM
Study NCT ID:
NCT04314934
Status:
COMPLETED
Last Update Posted:
2024-08-12
First Post:
2019-12-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000544', 'term': 'Alzheimer Disease'}], 'ancestors': [{'id': 'D003704', 'term': 'Dementia'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D024801', 'term': 'Tauopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C568535', 'term': 'tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2', 'PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 300}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-10-10', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-08', 'completionDateStruct': {'date': '2024-06-14', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-08-09', 'studyFirstSubmitDate': '2019-12-12', 'studyFirstSubmitQcDate': '2020-03-17', 'lastUpdatePostDateStruct': {'date': '2024-08-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-03-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-06-14', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.03', 'timeFrame': '96 weeks', 'description': 'To continue assessing the safety and tolerability of ANAVEX2-73'}], 'secondaryOutcomes': [{'measure': 'ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition)', 'timeFrame': '96 weeks', 'description': 'Change from baseline to week 96 in cognition according to the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog)'}, {'measure': 'ADCS-ADL (Activities of Daily Living)', 'timeFrame': '96 weeks', 'description': "Change from baseline to week 96 in ability to perform daily activities according to the Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL)"}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Alzheimer Disease']}, 'referencesModule': {'references': [{'pmid': '39800452', 'type': 'DERIVED', 'citation': "Macfarlane S, Grimmer T, Teo K, O'Brien TJ, Woodward M, Grunfeld J, Mander A, Brodtmann A, Brew BJ, Morris P, Short C, Kurrle S, Lai R, Bharadwaj S, Drysdale P, Sturm J, Lewis SJG, Barton D, Kalafatis C, Sharif S, Perry R, Mannering N, MacSweeney JE, Pearson S, Evans C, Krishna V, Thompson A, Munisamy M, Bhatt N, Asher A, Connell S, Lynch J, Rutgers SM, Dautzenberg PL, Prins N, Oschmann P, Frolich L, Tacik P, Peters O, Wiltfang J, Henri-Bhargava A, Smith E, Pasternak S, Frank A, Chertkow H, Ingram J, Hsiung GR, Brittain R, Tartaglia C, Cohen S, Villa LM, Gordon E, Jubault T, Guizard N, Tucker A, Kaufmann WE, Jin K, Chezem WR, Missling CU, Sabbagh MN. Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial. J Prev Alzheimers Dis. 2025 Jan;12(1):100016. doi: 10.1016/j.tjpad.2024.100016. Epub 2025 Jan 1."}]}, 'descriptionModule': {'briefSummary': 'This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.', 'detailedDescription': 'This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '85 Years', 'minimumAge': '55 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Previous completion of participation in the ANAVEX2-73-AD-004 double-blind study.\n* Participants may be either outpatients, or residents of an assisted-living facility.\n* Participants must have a designated study partner, who spends at least 10hrs per week with the participant, in order that assessments e.g. carer burden instruments are completed with true knowledge of the participant.\n* No suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months (i.e. active suicidal thought(s) with intent but without specific plan, or active suicidal thought(s) with plan and intent) OR suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).\n* Confirmation from the participant that, if of childbearing potential is not pregnant through urine pregnancy testing.\n\nExclusion Criteria:\n\n* Adverse events (AEs) from the previous study (ANAVEX2-73-AD-004) that have not resolved, are moderate or severe, judged to be possibly related or related to study drug, and considered by the investigator to be a contraindication to extension study participation\n* Any condition or laboratory abnormality that would make the subject, in the judgment of the investigator, unsuitable for the study\n* Significant history of drug addiction (with the exception of nicotine dependence) or abuse (including alcohol, as defined in DSM-V or in the opinion of the investigator) within the last two years prior to informed consent, or a positive urine drug screen for cocaine, opioid, phencyclidine (PCP), amphetamine or marijuana at screening. Prescription medication yielding a positive drug screen are acceptable except for tricyclic antidepressants (e.g. Amitriptyline, Amoxapine, Desipramine, (Norpramin) Doxepin, Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil), Trimipramine (Surmontil)).\n* Any known hypersensitivity to any of the excipients contained in the study drug formulation.'}, 'identificationModule': {'nctId': 'NCT04314934', 'acronym': 'ATTENTION-AD', 'briefTitle': 'OLE of Phase 2b/3 Study ANAVEX2-73-AD-004', 'organization': {'class': 'INDUSTRY', 'fullName': 'Anavex Life Sciences Corp.'}, 'officialTitle': "Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004", 'orgStudyIdInfo': {'id': 'ANAVEX2-73-AD-EP-004'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Active', 'description': 'ANAVEX2-73', 'interventionNames': ['Drug: ANAVEX2-73']}], 'interventions': [{'name': 'ANAVEX2-73', 'type': 'DRUG', 'otherNames': ['Blarcamesine'], 'description': 'Oral capsules', 'armGroupLabels': ['Active']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Central Coast', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Central Coast Neurosciences Research', 'geoPoint': {'lat': -33.42979, 'lon': 151.37144}}, {'city': 'Hornsby', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Hornsby (Northern Sydney Health)', 'geoPoint': {'lat': -33.70244, 'lon': 151.09931}}, {'city': 'Hornsby', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Sydney', 'geoPoint': {'lat': -33.70244, 'lon': 151.09931}}, {'city': 'Macquarie Park', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'KaRa MINDS', 'geoPoint': {'lat': -33.78105, 'lon': 151.12757}}, {'city': 'Macquarie Park', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Sydney', 'geoPoint': {'lat': -33.78105, 'lon': 151.12757}}, {'city': 'Sydney', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Sydney', 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'city': 'Sydney', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'University of Sydney', 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'city': 'Sydney', 'state': 'NEW', 'country': 'Australia', 'facility': 'Sydney', 'geoPoint': {'lat': -33.86785, 'lon': 151.20732}}, {'city': 'Gold Coast', 'state': 'Queensland', 'country': 'Australia', 'facility': 'Gold Coast', 'geoPoint': {'lat': -28.00029, 'lon': 153.43088}}, {'city': 'Southport', 'state': 'Quennsland', 'country': 'Australia', 'facility': 'Gold Coast Memory Disorders Clinic', 'geoPoint': {'lat': -27.96724, 'lon': 153.39796}}, {'city': 'Adelaide', 'state': 'South Australia', 'country': 'Australia', 'facility': 'Adelaide', 'geoPoint': {'lat': -34.92866, 'lon': 138.59863}}, {'city': 'Belmont', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Melbourne', 'geoPoint': {'lat': -38.17485, 'lon': 144.34276}}, {'city': 'Geelong', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Geelong Private Medical Centre', 'geoPoint': {'lat': -38.14711, 'lon': 144.36069}}, {'city': 'Glen Iris', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Delmont Private Hospital', 'geoPoint': {'lat': -37.86667, 'lon': 145.06667}}, {'city': 'Malvern', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Hammond Care', 'geoPoint': {'lat': -37.86259, 'lon': 145.02811}}, {'city': 'Malvern', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Melbourne', 'geoPoint': {'lat': -37.86259, 'lon': 145.02811}}, {'city': 'Melbourne', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Austin Health', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'city': 'Melbourne', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Melbourne', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'city': 'Melbourne N.', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Melbourne'}, {'city': 'Nedlands', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'McCusker', 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'city': 'Delmont', 'country': 'Australia', 'facility': 'Melbourne', 'geoPoint': {'lat': -41.75636, 'lon': 147.16723}}, {'city': 'Malvern', 'country': 'Australia', 'facility': 'Hammond Health', 'geoPoint': {'lat': -37.86259, 'lon': 145.02811}}, {'city': 'Melbourne E.', 'country': 'Australia', 'facility': 'Melbourne'}, {'city': 'Calgary', 'state': 'Alberta', 'country': 'Canada', 'facility': 'Healthy Brain Aging Labs Uni of Calgary', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'city': 'Ottawa', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Bruyere Continuing Care', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'city': 'Peterborough', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Kawartha Centre', 'geoPoint': {'lat': 44.30012, 'lon': -78.31623}}, {'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Bay Crest Health Sciences', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Toronto Memory Program', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'city': 'Ulm', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'University of Ulm, Memory Clinic', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'city': 'Bayreuth', 'state': 'Bavaria', 'country': 'Germany', 'facility': 'Bayreuth Clinic, Hohe Warte Hospital', 'geoPoint': {'lat': 49.94782, 'lon': 11.57893}}, {'city': 'München', 'state': 'Bavaria', 'country': 'Germany', 'facility': 'Technical University of Munich, School of Medicine', 'geoPoint': {'lat': 48.69668, 'lon': 13.46314}}, {'city': 'Mannheim', 'state': 'Hesse', 'country': 'Germany', 'facility': 'Central Institute of Mental Health'}, {'city': 'Göttingen', 'state': 'Lower Saxony', 'country': 'Germany', 'facility': 'Goettingen University Medicine, Clinic for Psychiatry and Psychotherapy', 'geoPoint': {'lat': 51.53443, 'lon': 9.93228}}, {'city': 'Bonn', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'University Hospital, Bonn', 'geoPoint': {'lat': 50.73438, 'lon': 7.09549}}, {'city': 'Mainz', 'state': 'Rhineland-Palatinate', 'country': 'Germany', 'facility': 'Clinic for Psychiatry and Psychotherapy', 'geoPoint': {'lat': 49.98185, 'lon': 8.28008}}, {'city': 'Berlin', 'country': 'Germany', 'facility': 'Charite University Medicine', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': "'s-Hertogenbosch", 'country': 'Netherlands', 'facility': 'Brain Research Center', 'geoPoint': {'lat': 51.69917, 'lon': 5.30417}}, {'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'Brain Research Center', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'city': 'Zwolle', 'country': 'Netherlands', 'facility': 'Brain Research Center', 'geoPoint': {'lat': 52.5125, 'lon': 6.09444}}, {'city': 'Teesside', 'state': 'County Teesside', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research'}, {'city': 'Glasgow', 'state': 'Scotland', 'country': 'United Kingdom', 'facility': 'Glasgow Memory Clinic', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'city': 'Guildford', 'state': 'Surrey', 'country': 'United Kingdom', 'facility': 'Cognition Health', 'geoPoint': {'lat': 51.23536, 'lon': -0.57427}}, {'city': 'Barnsley', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research', 'geoPoint': {'lat': 53.55, 'lon': -1.48333}}, {'city': 'Blackpool', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research', 'geoPoint': {'lat': 53.81667, 'lon': -3.05}}, {'city': 'Cannock', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research', 'geoPoint': {'lat': 52.69045, 'lon': -2.03085}}, {'city': 'Leeds', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research', 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'city': 'Liverpool', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'city': 'London', 'country': 'United Kingdom', 'facility': 'Cognition Health', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'London', 'country': 'United Kingdom', 'facility': 'Imperial College', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'MAC Clinical Research', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'city': 'Plymouth', 'country': 'United Kingdom', 'facility': 'Cognition Health', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Anavex Life Sciences Corp.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Anavex Australia Pty Ltd.', 'class': 'INDUSTRY'}, {'name': 'Anavex Germany GmbH', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}